Tecentriq, Avastin Regimen Beats Anti-PD-L1 Monotherapy in MMR-Deficient, MSI-High Colorectal Cancer
Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...
Jazz Pharma to Submit Ziihera Data in First-Line HER2-Positive Gastroesophageal Cancer to Regulators
In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.
The firm is looking ahead to Phase III Kimmtrak results in cutaneous melanoma and early-stage readouts from its PRAME candidates.
So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.
The startup aims to create a platform for treating extremely rare genetic mutations, armed with CRISPR advances and new regulatory pathways.
The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.
Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how politics will impact innovation long term.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback